Actively Recruiting
Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML
Led by Wake Forest University Health Sciences · Updated on 2026-02-02
50
Participants Needed
2
Research Sites
246 weeks
Total Duration
On this page
Sponsors
W
Wake Forest University Health Sciences
Lead Sponsor
A
Atrium Health Levine Cancer Institute
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this research is to see how certain genetic variations relate to side effects and outcomes experienced while receiving treatment with azacitidine and venetoclax.
CONDITIONS
Official Title
Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Provide written informed consent and HIPAA authorization.
- Be 18 years of age or older at enrollment.
- Have a confirmed diagnosis of acute myeloid leukemia (AML).
- Plan to receive initial treatment with azacitidine and venetoclax.
- Be able to read and understand English or Spanish.
- Be able to understand and comply with study procedures for the entire study duration as judged by the investigator.
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Levine Cancer Institute
Charlotte, North Carolina, United States, 28204
Actively Recruiting
2
Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina, United States, 27157
Actively Recruiting
Research Team
C
Courtney Schepel
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here